Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to ...
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug ...
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...
Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...
It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback